Gastrointestinal Therapeutics-North America Market Status and Trend Report 2013-2023
Report Summary
Gastrointestinal Therapeutics-North America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Gastrointestinal Therapeutics industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole North America and Regional Market Size of Gastrointestinal Therapeutics 2013-2017, and development forecast 2018-2023
Main market players of Gastrointestinal Therapeutics in North America, with company and product introduction, position in the Gastrointestinal Therapeutics market
Market status and development trend of Gastrointestinal Therapeutics by types and applications
Cost and profit status of Gastrointestinal Therapeutics, and marketing status
Market growth drivers and challenges
The report segments the North America Gastrointestinal Therapeutics market as:
North America Gastrointestinal Therapeutics Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
United States
Canada
Mexico
North America Gastrointestinal Therapeutics Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Tablets
Injection
North America Gastrointestinal Therapeutics Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
IBD
Irritable Bowel Syndrome (IBS)
Other
North America Gastrointestinal Therapeutics Market: Players Segment Analysis (Company and Product introduction, Gastrointestinal Therapeutics Sales Volume, Revenue, Price and Gross Margin):
Johnson & Johnson
AbbVie
Allergan
Takeda
Novartis
Pfizer
GlaxoSmithKline
Merck
UCB (Belgium)
F. Hoffmann-La Roche
Eli Lilly
AstraZeneca
Procter & Gamble
Eisai
Shire Pharmaceuticals
Ferring Pharmaceuticals
Kyowa Hakko Kirin
Salix Pharmaceuticals
Ono Pharmaceutical
TSD Japan
RedHill Biopharma
Kaken Pharmaceutical
Amgen
Synergy Pharmaceuticals
Ajinomoto
Kissei Pharmaceutical
Hutchison Medi Pharma
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Gastrointestinal Therapeutics-North America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Gastrointestinal Therapeutics industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole North America and Regional Market Size of Gastrointestinal Therapeutics 2013-2017, and development forecast 2018-2023
Main market players of Gastrointestinal Therapeutics in North America, with company and product introduction, position in the Gastrointestinal Therapeutics market
Market status and development trend of Gastrointestinal Therapeutics by types and applications
Cost and profit status of Gastrointestinal Therapeutics, and marketing status
Market growth drivers and challenges
The report segments the North America Gastrointestinal Therapeutics market as:
North America Gastrointestinal Therapeutics Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
United States
Canada
Mexico
North America Gastrointestinal Therapeutics Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Tablets
Injection
North America Gastrointestinal Therapeutics Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
IBD
Irritable Bowel Syndrome (IBS)
Other
North America Gastrointestinal Therapeutics Market: Players Segment Analysis (Company and Product introduction, Gastrointestinal Therapeutics Sales Volume, Revenue, Price and Gross Margin):
Johnson & Johnson
AbbVie
Allergan
Takeda
Novartis
Pfizer
GlaxoSmithKline
Merck
UCB (Belgium)
F. Hoffmann-La Roche
Eli Lilly
AstraZeneca
Procter & Gamble
Eisai
Shire Pharmaceuticals
Ferring Pharmaceuticals
Kyowa Hakko Kirin
Salix Pharmaceuticals
Ono Pharmaceutical
TSD Japan
RedHill Biopharma
Kaken Pharmaceutical
Amgen
Synergy Pharmaceuticals
Ajinomoto
Kissei Pharmaceutical
Hutchison Medi Pharma
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF GASTROINTESTINAL THERAPEUTICS
1.1 Definition of Gastrointestinal Therapeutics in This Report
1.2 Commercial Types of Gastrointestinal Therapeutics
1.2.1 Tablets
1.2.2 Injection
1.3 Downstream Application of Gastrointestinal Therapeutics
1.3.1 IBD
1.3.2 Irritable Bowel Syndrome (IBS)
1.3.3 Other
1.4 Development History of Gastrointestinal Therapeutics
1.5 Market Status and Trend of Gastrointestinal Therapeutics 2013-2023
1.5.1 North America Gastrointestinal Therapeutics Market Status and Trend 2013-2023
1.5.2 Regional Gastrointestinal Therapeutics Market Status and Trend 2013-2023
CHAPTER 2 NORTH AMERICA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Gastrointestinal Therapeutics in North America 2013-2017
2.2 Consumption Market of Gastrointestinal Therapeutics in North America by Regions
2.2.1 Consumption Volume of Gastrointestinal Therapeutics in North America by Regions
2.2.2 Revenue of Gastrointestinal Therapeutics in North America by Regions
2.3 Market Analysis of Gastrointestinal Therapeutics in North America by Regions
2.3.1 Market Analysis of Gastrointestinal Therapeutics in United States 2013-2017
2.3.2 Market Analysis of Gastrointestinal Therapeutics in Canada 2013-2017
2.3.3 Market Analysis of Gastrointestinal Therapeutics in Mexico 2013-2017
2.4 Market Development Forecast of Gastrointestinal Therapeutics in North America 2018-2023
2.4.1 Market Development Forecast of Gastrointestinal Therapeutics in North America 2018-2023
2.4.2 Market Development Forecast of Gastrointestinal Therapeutics by Regions 2018-2023
CHAPTER 3 NORTH AMERICA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole North America Market Status by Types
3.1.1 Consumption Volume of Gastrointestinal Therapeutics in North America by Types
3.1.2 Revenue of Gastrointestinal Therapeutics in North America by Types
3.2 North America Market Status by Types in Major Countries
3.2.1 Market Status by Types in United States
3.2.2 Market Status by Types in Canada
3.2.3 Market Status by Types in Mexico
3.3 Market Forecast of Gastrointestinal Therapeutics in North America by Types
CHAPTER 4 NORTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Gastrointestinal Therapeutics in North America by Downstream Industry
4.2 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Major Countries
4.2.1 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in United States
4.2.2 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Canada
4.2.3 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Mexico
4.3 Market Forecast of Gastrointestinal Therapeutics in North America by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF GASTROINTESTINAL THERAPEUTICS
5.1 North America Economy Situation and Trend Overview
5.2 Gastrointestinal Therapeutics Downstream Industry Situation and Trend Overview
CHAPTER 6 GASTROINTESTINAL THERAPEUTICS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN NORTH AMERICA
6.1 Sales Volume of Gastrointestinal Therapeutics in North America by Major Players
6.2 Revenue of Gastrointestinal Therapeutics in North America by Major Players
6.3 Basic Information of Gastrointestinal Therapeutics by Major Players
6.3.1 Headquarters Location and Established Time of Gastrointestinal Therapeutics Major Players
6.3.2 Employees and Revenue Level of Gastrointestinal Therapeutics Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 GASTROINTESTINAL THERAPEUTICS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Johnson & Johnson
7.1.1 Company profile
7.1.2 Representative Gastrointestinal Therapeutics Product
7.1.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.2 AbbVie
7.2.1 Company profile
7.2.2 Representative Gastrointestinal Therapeutics Product
7.2.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of AbbVie
7.3 Allergan
7.3.1 Company profile
7.3.2 Representative Gastrointestinal Therapeutics Product
7.3.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Allergan
7.4 Takeda
7.4.1 Company profile
7.4.2 Representative Gastrointestinal Therapeutics Product
7.4.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Takeda
7.5 Novartis
7.5.1 Company profile
7.5.2 Representative Gastrointestinal Therapeutics Product
7.5.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Novartis
7.6 Pfizer
7.6.1 Company profile
7.6.2 Representative Gastrointestinal Therapeutics Product
7.6.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Pfizer
7.7 GlaxoSmithKline
7.7.1 Company profile
7.7.2 Representative Gastrointestinal Therapeutics Product
7.7.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.8 Merck
7.8.1 Company profile
7.8.2 Representative Gastrointestinal Therapeutics Product
7.8.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Merck
7.9 UCB (Belgium)
7.9.1 Company profile
7.9.2 Representative Gastrointestinal Therapeutics Product
7.9.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of UCB (Belgium)
7.10 F. Hoffmann-La Roche
7.10.1 Company profile
7.10.2 Representative Gastrointestinal Therapeutics Product
7.10.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche
7.11 Eli Lilly
7.11.1 Company profile
7.11.2 Representative Gastrointestinal Therapeutics Product
7.11.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Eli Lilly
7.12 AstraZeneca
7.12.1 Company profile
7.12.2 Representative Gastrointestinal Therapeutics Product
7.12.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca
7.13 Procter & Gamble
7.13.1 Company profile
7.13.2 Representative Gastrointestinal Therapeutics Product
7.13.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Procter & Gamble
7.14 Eisai
7.14.1 Company profile
7.14.2 Representative Gastrointestinal Therapeutics Product
7.14.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Eisai
7.15 Shire Pharmaceuticals
7.15.1 Company profile
7.15.2 Representative Gastrointestinal Therapeutics Product
7.15.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Shire Pharmaceuticals
7.16 Ferring Pharmaceuticals
7.17 Kyowa Hakko Kirin
7.18 Salix Pharmaceuticals
7.19 Ono Pharmaceutical
7.20 TSD Japan
7.21 RedHill Biopharma
7.22 Kaken Pharmaceutical
7.23 Amgen
7.24 Synergy Pharmaceuticals
7.25 Ajinomoto
7.26 Kissei Pharmaceutical
7.27 Hutchison Medi Pharma
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF GASTROINTESTINAL THERAPEUTICS
8.1 Industry Chain of Gastrointestinal Therapeutics
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF GASTROINTESTINAL THERAPEUTICS
9.1 Cost Structure Analysis of Gastrointestinal Therapeutics
9.2 Raw Materials Cost Analysis of Gastrointestinal Therapeutics
9.3 Labor Cost Analysis of Gastrointestinal Therapeutics
9.4 Manufacturing Expenses Analysis of Gastrointestinal Therapeutics
CHAPTER 10 MARKETING STATUS ANALYSIS OF GASTROINTESTINAL THERAPEUTICS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Gastrointestinal Therapeutics in This Report
1.2 Commercial Types of Gastrointestinal Therapeutics
1.2.1 Tablets
1.2.2 Injection
1.3 Downstream Application of Gastrointestinal Therapeutics
1.3.1 IBD
1.3.2 Irritable Bowel Syndrome (IBS)
1.3.3 Other
1.4 Development History of Gastrointestinal Therapeutics
1.5 Market Status and Trend of Gastrointestinal Therapeutics 2013-2023
1.5.1 North America Gastrointestinal Therapeutics Market Status and Trend 2013-2023
1.5.2 Regional Gastrointestinal Therapeutics Market Status and Trend 2013-2023
CHAPTER 2 NORTH AMERICA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Gastrointestinal Therapeutics in North America 2013-2017
2.2 Consumption Market of Gastrointestinal Therapeutics in North America by Regions
2.2.1 Consumption Volume of Gastrointestinal Therapeutics in North America by Regions
2.2.2 Revenue of Gastrointestinal Therapeutics in North America by Regions
2.3 Market Analysis of Gastrointestinal Therapeutics in North America by Regions
2.3.1 Market Analysis of Gastrointestinal Therapeutics in United States 2013-2017
2.3.2 Market Analysis of Gastrointestinal Therapeutics in Canada 2013-2017
2.3.3 Market Analysis of Gastrointestinal Therapeutics in Mexico 2013-2017
2.4 Market Development Forecast of Gastrointestinal Therapeutics in North America 2018-2023
2.4.1 Market Development Forecast of Gastrointestinal Therapeutics in North America 2018-2023
2.4.2 Market Development Forecast of Gastrointestinal Therapeutics by Regions 2018-2023
CHAPTER 3 NORTH AMERICA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole North America Market Status by Types
3.1.1 Consumption Volume of Gastrointestinal Therapeutics in North America by Types
3.1.2 Revenue of Gastrointestinal Therapeutics in North America by Types
3.2 North America Market Status by Types in Major Countries
3.2.1 Market Status by Types in United States
3.2.2 Market Status by Types in Canada
3.2.3 Market Status by Types in Mexico
3.3 Market Forecast of Gastrointestinal Therapeutics in North America by Types
CHAPTER 4 NORTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Gastrointestinal Therapeutics in North America by Downstream Industry
4.2 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Major Countries
4.2.1 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in United States
4.2.2 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Canada
4.2.3 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Mexico
4.3 Market Forecast of Gastrointestinal Therapeutics in North America by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF GASTROINTESTINAL THERAPEUTICS
5.1 North America Economy Situation and Trend Overview
5.2 Gastrointestinal Therapeutics Downstream Industry Situation and Trend Overview
CHAPTER 6 GASTROINTESTINAL THERAPEUTICS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN NORTH AMERICA
6.1 Sales Volume of Gastrointestinal Therapeutics in North America by Major Players
6.2 Revenue of Gastrointestinal Therapeutics in North America by Major Players
6.3 Basic Information of Gastrointestinal Therapeutics by Major Players
6.3.1 Headquarters Location and Established Time of Gastrointestinal Therapeutics Major Players
6.3.2 Employees and Revenue Level of Gastrointestinal Therapeutics Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 GASTROINTESTINAL THERAPEUTICS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Johnson & Johnson
7.1.1 Company profile
7.1.2 Representative Gastrointestinal Therapeutics Product
7.1.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.2 AbbVie
7.2.1 Company profile
7.2.2 Representative Gastrointestinal Therapeutics Product
7.2.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of AbbVie
7.3 Allergan
7.3.1 Company profile
7.3.2 Representative Gastrointestinal Therapeutics Product
7.3.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Allergan
7.4 Takeda
7.4.1 Company profile
7.4.2 Representative Gastrointestinal Therapeutics Product
7.4.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Takeda
7.5 Novartis
7.5.1 Company profile
7.5.2 Representative Gastrointestinal Therapeutics Product
7.5.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Novartis
7.6 Pfizer
7.6.1 Company profile
7.6.2 Representative Gastrointestinal Therapeutics Product
7.6.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Pfizer
7.7 GlaxoSmithKline
7.7.1 Company profile
7.7.2 Representative Gastrointestinal Therapeutics Product
7.7.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.8 Merck
7.8.1 Company profile
7.8.2 Representative Gastrointestinal Therapeutics Product
7.8.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Merck
7.9 UCB (Belgium)
7.9.1 Company profile
7.9.2 Representative Gastrointestinal Therapeutics Product
7.9.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of UCB (Belgium)
7.10 F. Hoffmann-La Roche
7.10.1 Company profile
7.10.2 Representative Gastrointestinal Therapeutics Product
7.10.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche
7.11 Eli Lilly
7.11.1 Company profile
7.11.2 Representative Gastrointestinal Therapeutics Product
7.11.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Eli Lilly
7.12 AstraZeneca
7.12.1 Company profile
7.12.2 Representative Gastrointestinal Therapeutics Product
7.12.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca
7.13 Procter & Gamble
7.13.1 Company profile
7.13.2 Representative Gastrointestinal Therapeutics Product
7.13.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Procter & Gamble
7.14 Eisai
7.14.1 Company profile
7.14.2 Representative Gastrointestinal Therapeutics Product
7.14.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Eisai
7.15 Shire Pharmaceuticals
7.15.1 Company profile
7.15.2 Representative Gastrointestinal Therapeutics Product
7.15.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Shire Pharmaceuticals
7.16 Ferring Pharmaceuticals
7.17 Kyowa Hakko Kirin
7.18 Salix Pharmaceuticals
7.19 Ono Pharmaceutical
7.20 TSD Japan
7.21 RedHill Biopharma
7.22 Kaken Pharmaceutical
7.23 Amgen
7.24 Synergy Pharmaceuticals
7.25 Ajinomoto
7.26 Kissei Pharmaceutical
7.27 Hutchison Medi Pharma
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF GASTROINTESTINAL THERAPEUTICS
8.1 Industry Chain of Gastrointestinal Therapeutics
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF GASTROINTESTINAL THERAPEUTICS
9.1 Cost Structure Analysis of Gastrointestinal Therapeutics
9.2 Raw Materials Cost Analysis of Gastrointestinal Therapeutics
9.3 Labor Cost Analysis of Gastrointestinal Therapeutics
9.4 Manufacturing Expenses Analysis of Gastrointestinal Therapeutics
CHAPTER 10 MARKETING STATUS ANALYSIS OF GASTROINTESTINAL THERAPEUTICS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
